Suppression of Osteoprotegerin Expression by Prostaglandin E2 Is Crucially Involved in Lipopolysaccharide-Induced Osteoclast Formation
- 15 February 2004
- journal article
- research article
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 172 (4) , 2504-2510
Abstract
LPS is a potent stimulator of bone resorption in inflammatory diseases. The mechanism by which LPS induces osteoclastogenesis was studied in cocultures of mouse osteoblasts and bone marrow cells. LPS stimulated osteoclast formation and PGE2 production in cocultures of mouse osteoblasts and bone marrow cells, and the stimulation was completely inhibited by NS398, a cyclooxygenase-2 inhibitor. Osteoblasts, but not bone marrow cells, produced PGE2 in response to LPS. LPS-induced osteoclast formation was also inhibited by osteoprotegerin (OPG), a decoy receptor of receptor activator of NF-κB ligand (RANKL), but not by anti-mouse TNFR1 Ab or IL-1 receptor antagonist. LPS induced both stimulation of RANKL mRNA expression and inhibition of OPG mRNA expression in osteoblasts. NS398 blocked LPS-induced down-regulation of OPG mRNA expression, but not LPS-induced up-regulation of RANKL mRNA expression, suggesting that down-regulation of OPG expression by PGE2 is involved in LPS-induced osteoclast formation in the cocultures. NS398 failed to inhibit LPS-induced osteoclastogenesis in cocultures containing OPG knockout mouse-derived osteoblasts. IL-1 also stimulated PGE2 production in osteoblasts and osteoclast formation in the cocultures, and the stimulation was inhibited by NS398. As seen with LPS, NS398 failed to inhibit IL-1-induced osteoclast formation in cocultures with OPG-deficient osteoblasts. These results suggest that IL-1 as well as LPS stimulates osteoclastogenesis through two parallel events: direct enhancement of RANKL expression and suppression of OPG expression, which is mediated by PGE2 production.Keywords
This publication has 53 references indexed in Scilit:
- Parathyroid Hormone Stimulates Receptor Activator of NFκB Ligand and Inhibits Osteoprotegerin Expression via Protein Kinase A Activation of cAMP-response Element-binding ProteinJournal of Biological Chemistry, 2002
- Modulation of the expression of cyclooxygenase‐2 by fatty acids mediated through Toll‐like receptor 4‐derived signaling pathways 1The FASEB Journal, 2001
- Intracellular Calcium and Protein Kinase C Mediate Expression of Receptor Activator of Nuclear Factor- B Ligand and Osteoprotegerin in OsteoblastsEndocrinology, 2000
- In Vivo Demonstration that Human Parathyroid Hormone 1–38 Inhibits the Expression of Osteoprotegerin in Bone with the Kinetics of an Immediate Early GeneJournal of Bone and Mineral Research, 2000
- Parathyroid Hormone Stimulates TRANCE and Inhibits Osteoprotegerin Messenger Ribonucleic Acid Expression in Murine Bone Marrow Cultures: Correlation with Osteoclast-Like Cell FormationEndocrinology, 1999
- Modulation of Osteoclast Differentiation and Function by the New Members of the Tumor Necrosis Factor Receptor and Ligand FamiliesEndocrine Reviews, 1999
- Endotoxin-tolerant Mice Have Mutations in Toll-like Receptor 4 (Tlr4)Journal of Experimental Medicine, 1999
- Osteotropic Agents Regulate the Expression of Osteoclast Differentiation Factor and Osteoprotegerin in Osteoblastic Stromal CellsEndocrinology, 1998
- Regulation of Osteoprotegerin mRNA Levels by Prostaglandin E2in Human Bone Marrow Stroma CellsBiochemical and Biophysical Research Communications, 1998
- Lipopolysaccharide antagonistsImmunology Today, 1992